Immuron Says US Navy Completes Interim Analysis of Drug for Campylobacter, Enterotoxigenic Escherichia Coli

MT Newswires Live10-04

Immuron (IMRN) said Friday that the US Naval Medical Research Command has completed an interim analysis for the clinical evaluation of a new oral drug to treat Campylobacter and Enterotoxigenic Escherichia coli.

The NMRC funded the study and Immuron produced a hyperimmune bovine colostrum product for testing in a controlled human infection model, the company said.

The interim results showed 10.4% protective efficacy against moderate to severe campylobacteriosis, Immuron said.

The company said the results are unrelated to its Travelan drug and do not affect its plans to hold end of phase 2 meeting with the US Food and Drug Administration with a view to initiating a phase 3 clinical trial of Travelan in H2 2025.

Immuron shares were 2.6% lower in recent trading.

Price: 2.67, Change: -0.07, Percent Change: -2.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472966884?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-04 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2472966884","market":"sg","top_or_hot":-1,"title":"Immuron Says US Navy Completes Interim Analysis of Drug for Campylobacter, Enterotoxigenic Escherichia Coli","media":"MT Newswires Live","content":"<html><body><p> Immuron (IMRN) said Friday that the US Naval Medical Research Command has completed an interim analysis for the clinical evaluation of a new oral drug to treat Campylobacter and Enterotoxigenic Escherichia coli.</p><p>The NMRC funded the study and Immuron produced a hyperimmune bovine colostrum product for testing in a controlled human infection model, the company said.</p><p>The interim results showed 10.4% protective efficacy against moderate to severe campylobacteriosis, Immuron said.</p><p>The company said the results are unrelated to its Travelan drug and do not affect its plans to hold end of phase 2 meeting with the US Food and Drug Administration with a view to initiating a phase 3 clinical trial of Travelan in H2 2025.</p><p>Immuron shares were 2.6% lower in recent trading.</p><p>Price: 2.67, Change: -0.07, Percent Change: -2.55</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuron Says US Navy Completes Interim Analysis of Drug for Campylobacter, Enterotoxigenic Escherichia Coli</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuron Says US Navy Completes Interim Analysis of Drug for Campylobacter, Enterotoxigenic Escherichia Coli\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-04 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immuron (IMRN) said Friday that the US Naval Medical Research Command has completed an interim analysis for the clinical evaluation of a new oral drug to treat Campylobacter and Enterotoxigenic ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMRN","symbol_name":"Immuron Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2472966884","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472966884","pubTimestamp":1728054300,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immuron  said Friday that the US Naval Medical Research Command has completed an interim analysis for the clinical evaluation of a new oral drug to treat Campylobacter and Enterotoxigenic Escherichia coli.The NMRC funded the study and Immuron produced a hyperimmune bovine colostrum product for testing in a controlled human infection model, the company said.The interim results showed 10.4% protective efficacy against moderate to severe campylobacteriosis, Immuron said.The company said the results are unrelated to its Travelan drug and do not affect its plans to hold end of phase 2 meeting with the US Food and Drug Administration with a view to initiating a phase 3 clinical trial of Travelan in H2 2025.Immuron shares were 2.6% lower in recent trading.Price: 2.67, Change: -0.07, Percent Change: -2.55","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMRN":"Immuron Ltd","BK4139":"生物科技"},"translate_title":"Immuron表示美国海军完成了弯曲杆菌、产肠毒素大肠杆菌药物的中期分析","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRN":0.9},"content_text":"Immuron (IMRN) said Friday that the US Naval Medical Research Command has completed an interim analysis for the clinical evaluation of a new oral drug to treat Campylobacter and Enterotoxigenic Escherichia coli.The NMRC funded the study and Immuron produced a hyperimmune bovine colostrum product for testing in a controlled human infection model, the company said.The interim results showed 10.4% protective efficacy against moderate to severe campylobacteriosis, Immuron said.The company said the results are unrelated to its Travelan drug and do not affect its plans to hold end of phase 2 meeting with the US Food and Drug Administration with a view to initiating a phase 3 clinical trial of Travelan in H2 2025.Immuron shares were 2.6% lower in recent trading.Price: 2.67, Change: -0.07, Percent Change: -2.55","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472966884"}